Eledon Pharmaceuticals, Inc.ELDNNASDAQ
LOADING
|||
Net Income Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-55.66%
↓ 27% below average
Average (39q)
-43.93%
Historical baseline
Range
High:271.40%
Low:-766.52%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -55.66% |
| Q2 2025 | -72.69% |
| Q1 2025 | 85.44% |
| Q4 2024 | -157.97% |
| Q3 2024 | 271.40% |
| Q2 2024 | -90.03% |
| Q1 2024 | 72.47% |
| Q4 2023 | -766.52% |
| Q3 2023 | 84.94% |
| Q2 2023 | -510.47% |
| Q1 2023 | 81.55% |
| Q4 2022 | -457.58% |
| Q3 2022 | -13.24% |
| Q2 2022 | 6.26% |
| Q1 2022 | -12.01% |
| Q4 2021 | 10.30% |
| Q3 2021 | -32.95% |
| Q2 2021 | 13.12% |
| Q1 2021 | -43.95% |
| Q4 2020 | 3.91% |
| Q3 2020 | -137.59% |
| Q2 2020 | 68.37% |
| Q1 2020 | -97.32% |
| Q4 2019 | -43.24% |
| Q3 2019 | 29.32% |
| Q2 2019 | 16.14% |
| Q1 2019 | -6.71% |
| Q4 2018 | -30.84% |
| Q3 2018 | -9.63% |
| Q2 2018 | -13.65% |
| Q1 2018 | -32.99% |
| Q4 2017 | 28.96% |
| Q3 2017 | 55.42% |
| Q2 2017 | -72.32% |
| Q1 2017 | -3.45% |
| Q4 2016 | 59.69% |
| Q3 2016 | 31.47% |
| Q2 2016 | -18.38% |
| Q1 2016 | -3.71% |
| Q4 2015 | 7.05% |